Evidence map›Paper›PMID 32564097›Full record

ReviewHerz2020

Prevention and treatment of venous thromboembolism in cancer patients.

Martina-Elisabeth Spehlmann, Norbert Frey, Oliver J Müller

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Martina-Elisabeth SpehlmannKlinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin), Universitätsklinikum Schleswig-Holstein, Arnold Heller-Str. 3, 24226, Kiel, Germany.
Norbert FreyKlinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin), Universitätsklinikum Schleswig-Holstein, Arnold Heller-Str. 3, 24226, Kiel, Germany.
Oliver J MüllerKlinik für Innere Medizin III (Kardiologie, Angiologie und Internistische Intensivmedizin), Universitätsklinikum Schleswig-Holstein, Arnold Heller-Str. 3, 24226, Kiel, Germany. oliver.mueller@uksh.de.
University of Lübeck · DEUniversity Hospital Schleswig-Holstein · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep vein thrombosis and pulmonary artery embolism are common and serious concomitant diseases in patients with cancer. The prophylaxis and therapy of such venous thromboembolic events (VTE) in oncology have so far been achieved with low-molecular-weight heparins. An increasing number of studies show evidence of the use of direct oral anticoagulants. However, since none of the possible options were shown to have a clear advantage in all patients, the individual decision to use a drug should be made depending on its effectiveness in preventing VTE, the risk of bleeding, the nature of the cancer, the interactions with other medications, the route of administration, and finally the cost of treatment.

Indexed as

NeoplasmsPulmonary EmbolismVenous ThromboembolismVenous ThrombosisAnticoagulantsHeparin, Low-Molecular-WeightHumansAnticoagulantsHeparin, Low-Molecular-WeightAnticoagulantsDeep vein thrombosisHeparinOncologyPulmonary embolismVenous thrombosis

Identifiers

PMID32564097
OpenAlexW3035769533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.